REPS2 Antibody (K-18): sc-100825

REPS2 Antibody (K-18) is a mouse monoclonal IgM antibody that detects REPS2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). REPS2 Antibody (K-18) is available as the non-conjugated anti-REPS2 antibody (K-18). REPS2 protein, primarily located in the cytoplasm, plays a crucial role in cellular signaling pathways, particularly in growth factor signaling. REPS2 is predominantly expressed in cerebellum, lung, testis, cerebrum, and kidney, highlighting its importance in various physiological processes. REPS2 interacts with several key proteins, including DDEF1 and paxillin, forming complexes essential for cellular functions. REPS2 also associates with activated RAL, involved in the Rho subfamily signaling pathway, particularly with Cdc42, and interacts with RAL BP-1, further influencing growth factor signaling. NFκB subunit p65 interaction with REPS2 EH domain suggests a regulatory role in inflammation and cell survival, as NFκB activity upregulation correlates with REPS2 activity downregulation. Decreased REPS2 expression during cancer progression may lead to dysregulation of growth factor signaling, contributing to uncontrolled cell proliferation and resistance to apoptosis, making REPS2 a significant factor in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

REPS2 Antibody (K-18) References:

1. Interaction of POB1, a downstream molecule of small G protein Ral, with PAG2, a paxillin-binding protein, is involved in cell migration.  |  Oshiro, T., et al. 2002. J Biol Chem. 277: 38618-26. PMID: 12149250
2. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells.  |  Oosterhoff, JK., et al. 2003. Oncogene. 22: 2920-5. PMID: 12771942
3. Organization and annotation of the Xcat critical region: elimination of seven positional candidate genes.  |  Huang, KM., et al. 2004. Genomics. 83: 893-901. PMID: 15081118
4. Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells.  |  Penninkhof, F., et al. 2004. Oncogene. 23: 5607-15. PMID: 15184881
5. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2.  |  Oosterhoff, JK., et al. 2005. Int J Cancer. 113: 561-7. PMID: 15455380
6. POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis.  |  Yadav, S., et al. 2005. Biochem Biophys Res Commun. 328: 1003-9. PMID: 15707977
7. Ubiquitin-interacting motifs of Epsin are involved in the regulation of insulin-dependent endocytosis.  |  Sugiyama, S., et al. 2005. J Biochem. 137: 355-64. PMID: 15809337
8. Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral.  |  Ikeda, M., et al. 1998. J Biol Chem. 273: 814-21. PMID: 9422736